Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
暂无分享,去创建一个
C. Adebamowo | O. Oladimeji | E. Ekong | R. Van den Bergh | A. Abimiku | N. Ndembi | S. Hinderaker | J. Obasanya | P. Isaakidis | J. Okuma | P. Dakum | Aderonke Agbaje | A. Osakwe | E. Ali | Osman Eltayeb | C. Mensah | Y. Avong | G. Akang | Bolajoko Oladunni Obembe
[1] D. Rosenbaum,et al. Clinical research coordinator handbook : GCP tools and techniques , 2015 .
[2] O. Oladimeji,et al. Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria , 2014, PloS one.
[3] A. Mantel‐Teeuwisse,et al. Adverse Events During Treatment of Drug-Resistant Tuberculosis: A Comparison Between Patients With or Without Human Immunodeficiency Virus Co-infection , 2013, Drug Safety.
[4] P. V. van Helden,et al. Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa , 2013, PloS one.
[5] A. Sandgren,et al. Adverse Events in Healthy Individuals and MDR-TB Contacts Treated with Anti-Tuberculosis Drugs Potentially Effective for Preventing Development of MDR-TB: A Systematic Review , 2013, PloS one.
[6] A. Diacon,et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial , 2012, The Lancet.
[7] G. Sotgiu,et al. Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India , 2012, PloS one.
[8] S. Pal,et al. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia , 2012, Southern med review.
[9] Gee Young Suh,et al. Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.
[10] C. Hallahan,et al. Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[11] A. O. Afolabi,et al. Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting among Healthcare Workers in a Tertiary Centre in Northern Nigeria , 2011 .
[12] O. Ogunleye,et al. The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, south west Nigeria , 2011, Pharmacoepidemiology and drug safety.
[13] O. Iribhogbe,et al. Extent of pharmacovigilance among resident doctors in Edo and Lagos states of Nigeria , 2010, Pharmacoepidemiology and drug safety.
[14] N. Awofeso. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. , 2008, Bulletin of the World Health Organization.
[15] J. Andrews,et al. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. , 2007, The Journal of infectious diseases.
[16] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[17] Douglas G Altman,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.
[18] A. Kehinde,et al. Multidrug resistance to Mycobacterium tuberculosis in a tertiary hospital. , 2007, Journal of the National Medical Association.
[19] I. Edwards,et al. WHO Programme – Global Monitoring , 2007 .
[20] B. Bıcakçı,et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[21] A. Rowhani-Rahbar,et al. Barriers to completion of tuberculosis treatment among prisoners and former prisoners in St. Petersburg, Russia. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[22] T. Holtz,et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study , 2005, The Lancet.
[23] P. Waller,et al. Regulatory Pharmacovigilance in the EU , 2002 .
[24] D. H. Mariam.,et al. Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[25] D. Kennedy,et al. Spontaneous Reporting in the United States , 2002 .
[26] J. Rho,et al. Counting the Costs of Drug-Related Adverse Events , 1999, PharmacoEconomics.
[27] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[28] N. Moore,et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. , 1998, British journal of clinical pharmacology.
[29] J. Griffin. Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. , 1986, British journal of clinical pharmacology.
[30] I. Oreagba,et al. Impact of training on Nigerian healthcare professionals' knowledge and practice of pharmacovigilance. , 2013, The International journal of risk & safety in medicine.
[31] J. Chinenye. HEALTH WORKERS AND HOSPITAL PATIENTS KNOWLEDGE OF PHARMACOVIGILANCE IN SOKOTO, NORTH-WEST NIGERIA , 2012 .
[32] E. Lopez-Gonzalez,et al. Determinants of Under-Reporting of Adverse Drug Reactions , 2009, Drug safety.
[33] L. Hazell,et al. Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.
[34] J. Bartlett,et al. Product information , 2001, Transplantation.
[35] H T McGuigan,et al. Health services. , 1975, The New Zealand medical journal.